| Effects of resistance exercise in prostate cancer patients: a meta-analysis M Keilani, T Hasenoehrl, L Baumann, R Ristl, M Schwarz, M Marhold, ... supportive Care in Cancer 25, 2953-2968, 2017 | 109 | 2017 |
| HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease G Semmler, EL Meyer, K Kozbial, P Schwabl, S Hametner-Schreil, ... Journal of hepatology 76 (4), 812-821, 2022 | 84 | 2022 |
| Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis M Jachs, L Hartl, B Simbrunner, D Bauer, R Paternostro, L Balcar, B Hofer, ... Clinical Gastroenterology and Hepatology 21 (9), 2318-2326. e7, 2023 | 42 | 2023 |
| Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non–small-cell Lung Cancer (NSCLC): A Report of 2 Cases M Schwarz, F Kocher, D Niedersuess-Beke, J Rudzki, M Hochmair, ... Clinical Lung Cancer 20 (3), e247-e250, 2019 | 31 | 2019 |
| Synthetic lethality guiding selection of drug combinations in ovarian cancer A Heinzel, M Marhold, P Mayer, M Schwarz, E Tomasich, A Lukas, ... PloS one 14 (1), e0210859, 2019 | 21 | 2019 |
| Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis C Schwarz, D Chromy, C Bangert, M Schwarz, M Jachs, T Reiberger, ... Journal of Hepatology 77 (1), 254-255, 2022 | 17 | 2022 |
| Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy C Schmidbauer, M Schwarz, A Schütz, R Schubert, C Schwanke, E Gutic, ... PLoS One 16 (6), e0252274, 2021 | 10 | 2021 |
| Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression M Jachs, M Panzer, L Hartl, M Schwarz, L Balcar, JV Camp, P Munda, ... JHEP Reports 5 (8), 100751, 2023 | 7 | 2023 |
| HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic L Hartl, M Jachs, D Bauer, B Simbrunner, D Chromy, T Binter, L Steininger, ... Journal of Viral Hepatitis 29 (12), 1062-1072, 2022 | 7 | 2022 |
| Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient M Jachs, L Hartl, B Simbrunner, G Semmler, L Balcar, BS Hofer, ... Journal of Hepatology, 2024 | 6 | 2024 |
| Endoscopic band ligation is safe despite low platelet count and high INR N Pfisterer, M Schwarz, M Jachs, F Putre, L Ritt, M Mandorfer, C Madl, ... Hepatology International, 1-10, 2023 | 6 | 2023 |
| An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis L Hartl, B Simbrunner, M Jachs, P Wolf, DJM Bauer, B Scheiner, L Balcar, ... JHEP Reports 5 (8), 100789, 2023 | 4 | 2023 |
| Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast M Marhold, E Tomasich, M Schwarz, S Udovica, A Heinzel, P Mayer, ... Oncotarget 9 (91), 36379, 2018 | 4 | 2018 |
| Late-stage presentation with decompensated cirrhosis is alarmingly common but successful etiologic therapy allows for favorable clinical outcomes M Schwarz, C Schwarz, L Burghart, N Pfisterer, D Bauer, W Hübl, ... Plos one 18 (8), e0290352, 2023 | 1 | 2023 |
| Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up C Schwarz, D Chromy, D Bauer, N Duong, VU Schmidbauer, M Schwarz, ... Wiener klinische Wochenschrift 135 (15-16), 420-428, 2023 | 1 | 2023 |
| Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to … M Schwarz, C Schwarz, A Schütz, C Schwanke, E Krabb, R Schubert, ... Journal of Virus Eradication 9 (1), 100319, 2023 | 1 | 2023 |
| Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality L Hartl, B Simbrunner, M Jachs, P Wolf, DJM Bauer, B Scheiner, L Balcar, ... JHEP Reports 6 (1), 100954, 2024 | | 2024 |
| ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria C Schwarz, D Bauer, L Dorn, M Jachs, L Hartl, D Chromy, ... Wiener klinische Wochenschrift, 1-11, 2023 | | 2023 |
| CHIME-A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers C Schwarz, R Schubert, M Schwarz, A Schütz, A Jenke, D Bauer, ... Journal of Virus Eradication 9 (3), 100338, 2023 | | 2023 |
